1. Kane J, Honigfeld G, Singer J, Meltzer H. (1988) Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psych. 45: 789–796.
2. Meltzer HY. (1988) Clozapine: Clinical advantages and biologic mechanisms. In: Schulz C, Tamminga C, Chase TN, Christensen AV, Gerlach J (eds). Schizophrenia: A Scientific Focus. Oxford University Press, New York, pp 302–309.
3. Peroutka SJ, Snyder SH. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiat. 137: 1518–1522.
4. Richelson E. (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J. Clin. Psychiat. 45: 331–336.
5. Seeman P. (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261–284.